Connect with us

Feedm

The Post-Pandemic World Will At Least Have Plenty of Sunshine

Published

on

Solar Automotive Tesla Stocks

Solar energy has exceeded all expectations with near-exponential growths while also becoming more affordable. Solar technology has advanced so much that besides winning the race when it comes to carbon emissions, it became cheaper than its fossil-fuel counterpart. And even Tesla Inc’s (NASDAQ:TLSA) flamboyant CEO and Berkshire Hathaway Inc’s (NYSE:BRKB) (NYSE:BRKA) the “Oracle of Omaha, Warren Buffett agree on its megawatt potential as the solar power energy market is projected to exceed $223 billion by 2026.

Earlier in May, Buffett has been approved to build the largest solar installation in U.S. history but Musk is just as ambitious in solar roofs as in EVs as Tesla plans 1,000 home installations per week within the next year along with a price-matching incentive program.

Amazon (NASDAQ:AMZN) is also entering the energy race as it will construct a 100MW solar energy facility in China as part of the five energy projects the company is planning around the globe. Meanwhile, one of the companies which is about to launch world’s first solar powered tonneau covers that will be disturbed through Amazon stated its factories in China have restarted after a very brief pause on March 16th. With its supply chain fully intact, Worksport owned by Franchise Holdings International (OTC:FNHI) is working on new products for the booming light truck market. On May 15th, the company reported its revenues jumped 300% in the fiscal year that ended on December 31st, 2019 with US revenues showing an even bigger increase of 347% compared to the same period last year. Along with its secured intellectual property, everything is coming together for this innovative company, even faster than expected.

Jinko Solar Holding (NYSE:JKS) even managed to deliver a milestone during these challenging times as the leading solar module manufacturer topped the list of suppliers to India during the January-March quarter. Recently the company also virtually launched its 2020 flagship Tiger Pro module series that generate a 40 percent higher output.

Obviously, solar power is not the solution to everything as we also need batteries to store that energy as there is no sunshine during nighttime but we also have wind and hydro energy so many renewables to choose from. Many contenders will compete in their abilities to harness the power of the Sun as the pandemic has only emphasized the importance of providing energy much more cheaply for people, business and industry while respecting this planet we call our home. What the post-COVID-19 world needs is a renewable energy revolution as COVID-19 hasn’t hit a pause button on climate change.

This article is not a press release and is contributed by Ivana Popovic who is a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . Ivana Popovic does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com Questions about this release can be send to ivana@iamnewswire.com

BenzingaEditorial

Closing a Light Earnings Week

Published

on

Stock Market Tumble

Recent earnings reports imply that the positive momentum that made its appearance early July is still in the air. Last week, Adobe (NASDAQ: ADBE) and FedEx (NYSE: FDX) treated us with blockbuster results that confirmed the favorable trends, contributing to overall recovery of the U.S. economy.

This week, it was up to Nike’s (NYSE: NKE) deliver a blockbuster earnings report. Its shares surged and lifted the Dow Jones industrial average as the sports retailer smashed both revenue and profit expectations.

US stocks rose on Wednesday on strong earnings and progress on the upcoming COVID-19 vaccine as Johnson & Johnson (NYSE: JNJ) announced it is starting the third phase of its candidate in a largest study to date that will enroll up to 60,000 participants.

On the other hand, this week was not so kind to Tesla (NASDAQ: TSLA) whose shares dropped after its Battery Day event on Tuesday failed to delight investors. Musk laid out a plan to get to a $25,000 EV it expects to begin selling in three years but without showing any tangible progress.

Gold fell but oil prices climbed. Oil’s international benchmark jumped 1%, to $42.15 per barrel as BP (NYSE: BP), Royal Dutch Shell (NYSE: RDS-A)(NYSE: RDS-B) and other European energy companies are restructuring their core business to dramatically reduce emissions while investing heavily in renewable energy. Meanwhile, the American oil giants Chevron (NYSE: CVX) and Exxon Mobil Corporation (NYSE: XOM) are going in a far different direction.

Although it’s premature, the early reports suggest there is hope for Q3 and improved outlook in a variety of sectors. As for the third quarter of 2020, total S&P 500 earnings are expected to decline 23.1% on 2.9% drop in revenues, which is an improvement from Q2 expectations and figures.

Next week, Thor Industries Inc (NYSE: THO), Conagra (NYSE: CAG), Constellation Brands (NYSE: STZ) Bed Bath and Beyond (NASDAQ: BBBY) will give their own contribution to solving the outlook puzzle.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

bullstockcanada

COVID-19 Fueled Demand for Specialized Auto Equipment Despite Headwinds

Published

on

US Auto Parts

AutoZone (NYSE: AZO) delivered an upbeat fiscal fourth-quarter earnings report but shares lost their early gains. The quarter reflected DIY demand continued into the summer, but a lack of government aid weighed on sales at the end of the period. Overall, three major industry players did good.

AutoZone

AutoZone earned $30.93 a share on revenue that rose 14% to $4.55 billion. Results exceeded estimates of $25.46 and $4.18 billion, respectively. The same period last year included an extra week, so once adjusted, sales climbed 21% and same-store sales were up 22%. Although this is the largest same-store sales leap in the company’s history, managed notices a slow down during the final four weeks of the quarter which coincides with the end of enhanced unemployment benefits. COVID-19 related costs for the period amounted to $83.9. During the quarter, AutoZone opened 65 new stores across the US, Mexico and Brazil. Following the report, AutoZone shares rose 0.7% but ended up down about 1.3%.

Advance Auto Parts

AutoZone’s stock has lost 1.7% year to date which is better than Advance Auto Parts (NYSE: AAP) which dropped 5 percent. Since its second-quarter earnings were reported one month ago, shares lost about 3.8% during that time and underperformed the S&P 500. But earnings of $2.92 per share for the quarter that ended on July 11th, 2020 marked a 46% increase compared to the same year. Revenue amounted to $2,501 million and exceeded  Zacks Consensus Estimate of $2,360 million. Revenue rose 7.3% from the year-ago quarter. During the second quarter, comparable store sales increased 7.5% year on year. Adjusted operating income climbed 42.2% to $279.3 million on a year-over-year basis.

O’Reilly Automotive

AutoZone’s stock is below the 5% gain for O’Reilly Automotive (NASDAQ: ORLY). However, the performance of the retailer of aftermarket car supplies and tools was not consistent. Shares did manage to double since March lows as business performance was strong throughout the second quarter. Same-stores sales increased 16.2% as O’Reilly serves both the individual DIY as well as the professional DIFM professional customer which improved significantly as the quarter progressed. Analysts find O’Reilly’s dual-market approach is the best developed among its national peers.

What about EV equipment?

There are more competitors to think of as the innovative truck tonneau cover manufacturer Worksport (OTC: WKSP) entered into two agreements well-known electric truck producers which will benefit from its TerraVis™ solar charging system. On September 22nd, Worksport announced it is teaming up with Atlis Motor Vehicles. Electric vehicles come with a whole new set of advanced parts with hefty price tags as compared to their ICE counterparts, so it remains to be seen how will ICE automotive parts players adapt to the electric era.

Outlook

Auto parts stocks were hit by the pandemic because people drove less as they were forced to stay home. Yet at the same time, due the urgent nature of car repairs, followed with economic uncertainty and job losses, more people felt inclined to fix their current cars rather than buy new ones. This latter was stronger this time and AutoZone capitalized on the DIY trend.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

Vaccine Updates

Published

on

Corona Virus and the Stock Market

Besides saving lives and the global economy, we are expecting three things from the upcoming COVID-19 vaccine: safety, immunogenicity and efficacy. But we never had a 100 per cent efficacy when it comes to respiratory viruses, so anything between 50 and 100% will be the best we’ve got as the WHO believes everything above 50 per cent efficacy is acceptable. So, how far away are we from this goal?

Buoyed by positive results in its earlier studies, Johnson & Johnson (NYSE: JNJ) has now entered the final stage of clinical trials for its COVID-19 candidate. Although they started a couple of months behind others in the US, its trials will by far be largest with 60,000 enrolled participants.

The advantage of J&J candidate – one dose and no sub-zero storage temperatures

J&J’s vaccine is made with slightly different technology than others as it is modeled on its prior Ebola vaccine. It could result in considerable advantages over some of its competitors in terms of dosage and storage. But it’s up to Phase 3 trials that compare the effects of a vaccine with those of a placebo to determine if a single dose is indeed effective.

Disadvantages of Moderna and Pfizer candidates – significant logistics hurdle

Adenovirus vaccines must be kept refrigerated but not frozen, unlike the two front-runner vaccines, by Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). These depend on bits of genetic material known as mRNA. Besides the freezing requirement that makes distribution problematic, there vaccines also need to be taken in two doses, a few weeks apart.

Side-effects

When participants received a dose more than double the strength of the current shot of Moderna vaccine, 20 per cent experienced significant adverse effects such as fever and severe headaches. AstraZeneca was forced to pause its study for the same reason. Although the trial resumed in the UK and elsewhere, the research remains on hold in the US.

Candidates – US

Johnson & Johnson is now the fourth company to begin large-scale clinical trials for a COVID-19 vaccine in the United States, behind Moderna, Pfizer/BioNTech (NASDAQ: BNTX) and AstraZeneca (NYSE: AZN). According to Anthony S. Fauci M.D., this is an unprecedented speed made possible by decades of progress in vaccine technology and a coordinated approach that expanded beyond the scientific community, supported by governments and industries.

Candidates- Global

Financial Times has reported that there is a total of more than 300 vaccine candidates, according to the World Health Organization. Less than half are being tested on humans. Only nine of those have reached phase 3 trails which is the final stage before possible implementation. One of the nine vaccines is UK’s Astrazaneca. Two of the most advanced US candidates come from pharmaceutical company Pfizer, in partnership with Germany’s BioNTech, and Moderna. Four vaccines are being produced in China by Sinovac Biotech and one in Russia by the Gamaleya Research Institute which just boarded the phase 3 train this month. Then, there are CanSino Biologics (OTC: CASBF) and Sinopharm (OTC: SHTDY), which has two different shots in development and one is being led by Johnson & Johnson. All nine have already signed purchase agreements with governments around the world.

Countries

According to data from Deutsche Bank, the UK has built the largest and most diversified vaccine portfolio, on a per-capita basis, having pre-ordered more than five doses per citizen spread across six leading vaccine candidates. It is closely followed by US, Canada and Japan.

When it comes to the overall spender, the US government’s Biomedical Advanced Research and Development Authority has distributed more than $10 billion in funding for vaccine candidates, either via direct financing or through vaccine procurement agreements.

Canada has allocated $1 billion to secure at least 154 million doses of a future vaccine, signing deals with Pfizer, Moderna Inc, Johnson & Johnson, and Novavax (NASDAQ: NVAX) and most recently, Sanofi (NASDAQ: SNY).

The goal

The stated objective of the AstraZeneca, Moderna, Pfizer/BioNTech and J&J vaccines is to prevent the life-endangering symptoms of Covid-19. Their goal is to prevent people being admitted to hospital, going to intensive care and dying, as summarized by Andrew Pollard, who is leading the AstraZeneca trials at Oxford university. But preventing an asymptomatic infection entirely is likely to be a much bigger hurdle. Given the growing chorus of experts warning that vaccines will only offer a temporary immunity, making subsequent shots just as important. Only Johnson and Johnson and CanSino Biologics Inc are aiming for single dose shots.

If successful, Johnson & Johnson expects the first doses to be up for emergency use authorization from the US FDA at the beginning of  next year, while on track to make a billion doses a year. If this is the case, it would greatly help efforts to curb the pandemic.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading
Advertisement

Submit an Article

Send us your details and the subject of your article and an IAM editor will be in touch with you shortly

Trending